Format

Send to

Choose Destination
Menopause. 2004 Jan-Feb;11(1):34-9.

Low-dose transdermal estradiol for symptomatic perimenopause.

Author information

1
Departments of Obstetrics and Gynecology and Molecular Genetics, and Division of Reproductive Genetics, College of Medicine, University of Illinois at Chicago, Chicago, IL 60611, USA. lps5@cornell.edu

Abstract

OBJECTIVE:

To determine whether low-dose transdermal estrogen therapy is associated with a reduction in vasomotor symptoms in women who continue to have menstrual cycles.

DESIGN:

An open-label, observational evaluation conducted over 12 months in 22 consecutive perimenopausal women with vasomotor symptoms.

RESULTS:

Improvement in vasomotor symptoms was reported by 16 (73%) of women evaluated. Of responders, 11 characterized symptom relief as complete and 6 as moderate. Fifteen (68%) of the women remained on transdermal estrogen at 12 months. No adverse health-related events were attributed to estrogen therapy.

CONCLUSION:

Low-dose transdermal estrogen is well tolerated and was associated with a reduction in complaints of vasomotor symptoms before menopause. The steady-state pharmacokinetics of transdermal delivery of unopposed estrogen may be advantageous in a population sensitive to fluctuations in circulating hormone levels.

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wolters Kluwer
Loading ...
Support Center